Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Unknown 4Not yet recruiting 3Completed 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Trastuzumab 2Taxes 2Tamoxifen 2Interleukin-2 2Fluorouracil 2Cyclophosphamide 2Biopsy 2Anastrozole 2trastuzumab biosimilar HLX02 1taletrectinib 1palbociclib 1fluzoparib 1exemestane 1eribulin 1binimetinib 1aldesleukin 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tablets 1Receptors, Chimeric Antigen 1Radiotherapy 1Radiosurgery 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × fluzoparib × Breast × Clear all
NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Sun Yat-sen University

Phase 2 Suspended
80 enrolled
Breast

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡